2026–2027 CTCTC Young Investigator Research Fund
Issued by the Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing), two rounds of funding calls for the 2026–2027 China Tuberculosis Clinical Trials Consortium (CTCTC) Young Investigator Research Fund have been released in March and May 2026 respectively, targeting clinical and implementation research on tuberculosis rather than basic science. The full research cycle runs from April 1, 2026 to December 31, 2027, requiring all projects to finish data collection, analysis and summary within two years.
The main program launched in March accepts general tuberculosis clinical studies, planning to fund 6–8 projects with a budget of 30,000 to 50,000 RMB each. To fill research gaps in anti-tuberculosis drug safety monitoring, a targeted supplementary program was later opened with a narrowed scope: it prioritizes research on adverse events (AEs) management, optimized medication and anti-tuberculosis drug-induced liver injury (DILI), supporting 2–4 eligible projects with identical single-project funding.
All principal investigators must be clinical or prevention professionals from member institutions of IATB and CTCTC, under 45 years old (born after January 1, 1981) with associate senior or above professional titles. Research proposals from CTCTC member hospitals are prioritized, and hospital administrators are discouraged from serving as project leads. Applicants must promise regular progress and financial reports, and share research outputs with the alliance, which shall be acknowledged in all publications and academic presentations.
For application submission, the main program closed on April 5, 2026 with a two-round review including online defense, while the supplementary program’s deadline is May 31, 2026. Fully stamped application forms shall be emailed to the designated mailbox with standardized email subject lines. Successful projects receive financial support and professional technical guidance from the alliance’s expert panel to solve practical clinical difficulties in tuberculosis care.